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Abstract	57	 	58	
Improving	haematopoietic	cell	transplantation	outcomes	by	selection	of	an	HLA	59	 matched	unrelated	donor	is	best	practice,	however	donor	selection	by	secondary	60	 characteristics	is	controversial.	We	studied	1271	recipients	with	haematological	61	 malignancies	who	underwent	T	cell	depleted	allografts	and	who	had	complete	62	 data	on	HLA	matching	status	for	six	loci	(HLA-A,	-B,	-C,	-DRB1,	-DQB1,	-DPB1)	and	63	 clinical	outcome	data.	5-year	overall	survival	was	40.6%.	HLA	mismatching	(at	64	 HLA-A,	-B,	-C,	-DRB1,	-DQB1)	(Relative	Risk	(RR)	1.22,	95%	CI	1.2-1.5,	p=0.033	for	65	 1	mismatch	and	RR	1.46,	95%	CI	1.1-1.9,	p=0.009	for	>1	mismatch)	and	CMV	66	 mismatching	(RR	1.37,	95%	CI	1.2-1.6,	p<0.001)	were	significantly	associated	67	 with	inferior	survival.	Donors	under	30	years	were	associated	with	a	trend	68	 towards	better	survival	(RR	1.17,	95%	CI	0.99-1.4,	p=0.069).	In	a	multivariate	69	 model	for	mortality	combining	CMV	and	HLA	match	status,	we	found	a	RR	of	1.36	70	 (95%	CI	1.1-1.7,	p=0.003)	for	HLA	matched/CMV	mismatched,	a	RR	of	1.22	(95%	71	 CI	0.99-1.5,	p=0.062)	for	HLA	mismatched/CMV	matched	and	a	RR	of	1.81	(95%	72	
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CI	1.4-2.3,	p=<0.001)	for	HLA/	CMV	mismatched,	compared	to	the	HLA/CMV	73	 matched	recipients.	These	data	suggest	that	HLA	and	CMV	matching	status	should	74	 be	considered	when	selecting	unrelated	donors	and	that	CMV	matching	may	75	 abrogate	the	effect	of	an	HLA	mismatch.	76	
	77	 	78	
Introduction	79	 	80	 Haematopoietic	cell	transplantation	(HCT)	is	curative	for	many	recipients	81	 suffering	from	haematological	and	immunological	disorders.	Survival	using	82	 unrelated	donors	(UD)	has	improved	significantly	over	time	and	is	now	equal	to	83	 that	of	sibling	transplants	in	many	settings.(1)	A	reason	for	this	improvement	is	84	 the	enormous	expansion	in	the	internationally	available	UD	pool,	with	over	25	85	 million	donors	listed	on	Bone	Marrow	Donors	Worldwide	(BMDW)	in	2015	86	 (http://www.bmdw.org/accessed	20/4/2015).	HLA	matching	for	10/10	loci	is	87	 often	considered	the	gold	standard,	but	the	importance	of	HLA-DQB1	matching	88	 has	been	questioned.(2,	3)	Conversely,	the	additional	benefit	to	matching	for	89	 DPB1	has	been	increasingly	studied.(4-6)	In	addition,	studies	report	a	differential	90	 impact	of	single	allele	mismatches	on	transplant	outcomes.(2,	7,	8)	Due	to	the	91	 expansion	in	volunteer	donors	numbers	recipients	now	often	have	a	choice	92	 between	several	equally	HLA	matched	donors	and	in	this	setting	secondary	donor	93	 characteristics	such	as	donor	age,	gender,	parity,	CMV	serostatus	and	ABO	type	94	 should	be	taken	into	account.(3,	9)	Although	these	factors	may	currently	be	95	 considered	by	the	team	making	the	final	donor	selection,	no	widespread	96	
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internationally	agreed	selection	algorithms	are	available.	Selection	of	these	97	 factors	has	changed	significantly	over	time.		CMV	seronegative	donors	(D-)	were	98	 originally	chosen	for	all	recipients.	More	recently	a	CMV	seropositive	donor	has	99	 been	preferred	for	a	CMV	positive	recipient,	however	this	remains	controversial,	100	 despite	some	studies	supporting	it.(10,	11)	Studies	show	that	younger	donors	101	 generally	result	in	improved	outcomes,	but	the	impact	of	ABO	mismatches	and	102	 the	use	of	female	donors	have	produced	conflicting	results.	(3,	9)	103	 	104	 The	aim	of	this	study	was	to	analyse	the	impact	of	HLA	and	non-HLA	donor	105	 factors	on	transplant	outcomes	and	to	identify	those	factors	important	in	donor	106	 selection.		107	 	108	
Recipients,	material	and	methods	109	
	110	
Study	population	111	
	112	 The	final	study	population	includes	1271	UK	recipients,	both	children	and	adults,	113	 transplanted	for	a	haematological	malignancy,	from	September	1996	to	October	114	 2011,	from	an	UD	through	Anthony	Nolan.	1370	paired	samples	that	were	115	 collected	pre-transplant	or	pre-donation	for	recipients	and	donor	respectively	116	 and	stored	in	the	sample	repository	were	successfully	typed,	however	99	117	 recipients	were	not	included	in	the	final	study	population	due	to	incomplete	118	 clinical	data.	Both	recipient	and	donor	were	required	to	have	two	field	119	 (previously	4-digit)	allele	typing	results	at	six	HLA	loci	(HLA-A,	-B,	-C,	-DRB1,	-120	 DQB1,	-DPB1).	Clinical	data	were	collected	by	the	Anthony	Nolan	Research	121	
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Institute	in	collaboration	with	the	British	Society	for	Blood	and	Marrow	122	 Transplantation,	using	standard	post	transplant	reporting	forms.	Standard	123	 definitions	for	primary	graft	failure	(PGF),	graft	versus	host	disease	(GVHD)	and	124	 non-relapse	mortality	(NRM)	were	used.		Relapse	was	defined	as	clinical	evidence	125	 of	disease.	The	EBMT	score	was	calculated	based	on	the	publication	by	Gratwohl	126	
et	al.(12)	CMV	prophylaxis	was	not	routinely	given,	instead	screening	and	pre-127	 emptive	treatment	strategies	were	used.	128	
Ethical	permission	129	
The	study	has	ethical	approval	from	the	United	Kingdom’s	National	Research	130	 Ethics	Service	(www.myresearchproject.org.uk,	application	number	MREC	131	 01/8/31).	All	recipients	and	donors	signed	informed	consent.		132	
Statistical	Methods	133	
Probability	curves	were	calculated	using	the	Kaplan-Meier	method	for	survival	134	 and	the	cumulative	incidence	procedure	for	NRM	and	relapse.	Time	intervals	135	 were	calculated	relative	to	the	date	of	transplantation,	until	the	event	of	interest	136	 (or	competing	event),	or	until	the	date	of	last	follow-up.		Groups	were	compared	137	 using	either	the	log	rank	test	or	Gray’s	test	as	appropriate.	Factors	found	to	be	138	 significant	at	the	P	<	0.1	level	were	entered	into	either	Cox	regression	or	Fine	and	139	 Gray	(13)	models,	using	a	backward	stepping	procedure	to	find	the	best	model.	140	 Incomplete	time	to	event	data	for	PGF	and	Grade	II-IV	aGVHD	resulted	in	these	141	 outcomes	being	described	as	simple	proportions,	with	logistic	regression	analysis	142	 being	utilised	to	find	significant	factors	associated	with	each	outcome.	All	143	 analyses	were	performed	using	either	SPSS	version	22	software	(SPSS,	Inc.,	144	
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Chicago,	IL)	or	R	(14).		All	statistical	tests	were	2	sided,	and	P	<	0.05	was	used	to	145	 indicate	statistical	significance.	146	
Results	147	
	148	 Recipient	and	donor	factors	are	shown	in	Table	1	arranged	by	transplantation	149	 era.	Disease	for	which	transplantation	was	performed	were	acute	leukaemia	(581,	150	 46%),	myelodysplasia	(221,	17%),	chronic	leukaemia	(174,	14%),	lymphoma	151	 (198,	16%),	myeloma	(46,	4%)	and	other	(51,	4%).	94%	of	the	population	152	 received	T	cell	depletion	(TCD)	with	Alemtuzumab.	As	expected,	the	use	of	153	 myeloablative	conditioning	decreased	over	the	eras	with	a	corresponding	154	 increase	in	the	use	of	Peripheral	Blood	Stem	Cells	(PBSC).	Recipients	were	155	 significantly	older	in	the	later	eras.	There	was	a	reduction	in	the	number	of	HLA	156	 mismatched	donors	over	time.	Donors	were	also	more	likely	to	be	younger	and	157	 CMV	seropositive	donors	(D+)	were	more	likely	to	be	selected	for	CMV	158	 seropositive	recipients	(R+)	in	the	later	eras.		159	
	160	 The	5yr	probability	of	survival	for	the	whole	group	was	40.6%,	with	NRM	at	1,	3	161	 and	5	years	of	26.5%,	34.3%	and	37.4%	respectively.	The	relapse	risk	at	1,	3	and	162	 5	years	was	29.2	%,	39.2%	and	42.1%	respectively.	Overall	PGF	rate	was	3.8%.	163	 Acute	GVHD	was	present	in	28%	of	recipients	(grade	2	in	18%,	grade	3/4	in	10%).		164	 	165	
Factors	implicated	in	recipient	survival	and	mortality	166	
	167	
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Results	of	the	univariate	analysis	of	recipient	and	donor	factors	are	shown	in	168	 Table	2.	Older	recipients	(p=0.005),	R+	(p=0.013),	those	who	had	a	previous	169	 autograft	(p=0.001)	and	intermediate	or	poor	EBMT	risk	status	(p<0.001)	had	a	170	 worse	OS.	There	was	a	trend	to	a	worse	OS	with	the	use	of	Bone	Marrow	(BM)	171	 compared	to	PBSC	(p=0.078).	172	
	173	 Recipients	matched	for	10/10	HLA	alleles	had	significantly	better	OS	and	reduced	174	 NRM	compared	to	those	matched	at	9/10	or	<9/10	(5yr	OS:	43.1	vs	35.6	vs	28.4	175	 respectively,	p=0.001	(Figure	1)	and	NRM	at	1yr	:	20.3%	vs	26.0%	vs	33.4%	176	 respectively,	p=0.007).	Considering	individual	locus	mismatches	compared	to	177	 10/10	matched	recipients,	mismatching	for	HLA-B	(p=0.011)	and	–DQB1	178	 (p=0.03)	resulted	in	a	significantly	worse	survival,	while	mismatching	for	HLA-A	179	 (p=0.17),	-C	(p=0.28)	or	-DRB1	(p=0.75)	resulted	in	no	statistically	significant	180	 difference	in	survival	(table	2).		181	 	182	 HLA-DPB1	matching	was	not	associated	with	a	statistically	significant	survival	183	 advantage	(5yr	OS	for	12/12	was	46.5%	vs	42.5%	in	10/10	matches,	p=0.1).		Non-184	 permissive	HLA-DPB1	T-cell	Epitope	(TCE)	matching	status	was	associated	with	a	185	 trend	towards	worse	survival	and	a	significantly	higher	NRM	5yr	OS	in	DPB1	TCE	186	 matched,	allele	matched	or	TCE	mismatched	pairs	was	43.0%,	41.5%,	and	36.9%	187	 respectively,	p=0.054)	and	NRM	at	1	year	was	19.3%,	23.6%	and	26.4%	188	 respectively,	p=0.028	(Table	2).	189	 	190	 There	was	no	impact	of	donor	CMV	on	either	OS	or	NRM	as	an	independent	191	 variable,	however	a	significant	effect	was	observed	for	CMV	matching	status	192	
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between	recipient	and	donor.	Recipients	who	had	a	CMV	matched	donor	had	an	193	 OS	of	44.1%	vs	32.2%	for	those	who	were	mismatched	(p<0.001).		Survival	in	the	194	 R+/D+	setting	was	40.5%	compared	to	30.0%	in	the	R+/D-.	We	also	noted	a	195	 difference	in	the	CMV	negative	recipient	where	R-/D-	had	a	survival	of	45.3%	196	 compared	to	37.9%	in	the	R-/D+	(Table	2).	NRM	at	1	year	was	19.1%	vs	30.4%	197	 for	the	CMV	matched	vs	mismatched	recipients	(p<0.001)	(Table	2).	Use	of	donors	198	 under	the	age	of	30	resulted	in	a	better	survival	(45.3%	vs	38.6%,	p=0.01)	and	a	199	 trend	to	lower	NRM	(19.2%	vs	27.9%,	p=0.075).	An	ABO	match	or	minor	200	 mismatch	was	preferential	to	a	major	or	bidirectional	mismatch	(OS:	p=0.011and	201	 NRM:	p=0.040).	202	 	203	 In	multivariate	analysis	(Table	3),	the	only	recipient	factor	resulting	in	worse	OS	204	 was	older	age.	Recipients	with	a	previous	autograft	and/or	intermediate	or	poor	205	 EBMT	disease	risk	score	had	a	worse	OS.		OS	and	NRM	were	significantly	worse	in	206	 those	who	had	a	transplant	prior	to	2004	and	2000	respectively.	HLA	matching	207	 remained	significant,	as	those	who	had	>1	HLA	mismatch	with	their	donor	had	a	208	 Relative	Risk	(RR)	of	1.43	(95%	CI	1.1-1.9,	p=0.016)	for	mortality	and	1.59	(95%	209	 1.1-2.4,	p=0.028)	for	NRM.	Although	there	remained	a	survival	detriment	when	210	 comparing	a	single	mismatch	to	recipients	with	a	10/10	matched	donor	(OS:	RR	211	 1.21	(95%	CI	1.1-1.5),	p=0.042)	there	was	no	significant	impact	on	NRM:	RR	1.24	212	 (95%	CI	0.9-1.6),	p=0.14).	Recipients	who	were	CMV	mismatched	with	their	213	 donor	had	a	significant	survival	detriment	(OS:	RR	1.40,	95%	CI	1.2-1.6,	p<0.001;	214	 NRM:	RR	1.63,	95%	CI	1.3-2.1,	p<0.001.	Use	of	donors	>30	showed	a	trend	215	 towards	worse	OS	(RR	1.17	(95%	CI	0.98-1.4,	p=0.078),	but	no	impact	on	NRM.		In	216	 contrast,	recipient/donor	gender	matching	did	not	impact	on	OS,	while	a	female	217	
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donor	into	a	male	recipient	showed	a	trend	to	higher	NRM	compared	to	all	other	218	 gender	combinations	(RR	1.38,	95%	CI,	0.99-1.9,	p=0.063).	Recipient	donor	ABO	219	 matching	status	and	the	DPB1	TCE	were	not	significant	for	either	OS	or	TRM.	220	
	221	
Disease	Relapse	222	 Four	factors	were	shown	to	be	associated	with	an	increase	in	disease	relapse	in	223	 univariate	analysis,	including	recipients	of	a	prior	autograft	(5	yrs:	54.2%	vs	224	 40.0%,	p<0.001);	earlier	transplant	era	(p=0.012);	BM	vs	PBSC	(45.2%	vs	38.7%,	225	 p=0.024	and	the	use	a	DPB1	TCE	or	allele	matched	donor	vs	a	TCE	mismatch	226	 donor	(p=0.036).	CMV	status	of	either	the	patient	or	donor,	or	the	combinations,	227	 were	not	associated	with	relapse	risk.	In	multivariate	analysis,	donor	CMV	status	228	 was	the	only	donor	factor	associated	with	relapse	(D+:	RR	1.23	95%	CI	1.1-1.5,	229	 p=0.035),	whilst	prior	autograft	and	era	retained	significance	(Table	4).	230	
	231	
CMV	status	in	the	context	of	HLA	matching	232	
	233	 We	further	examined	the	relationship	between	recipient/donor	CMV	and	HLA	234	 matching	(Figure	2a).		Outcomes	differed	significantly	based	on	the	four	possible	235	 combinations	(p=<0.001).	In	the	HLA	matched	setting,	survival	was	significantly	236	 better	in	those	who	were	CMV	matched	(n=676)	compared	to	CMV	mismatched	237	 (n=223)	(5yr	OS	45.9%	vs	35.9%,	p=0.007).	Likewise,	in	the	HLA	mismatched	238	 setting,	CMV	matched	recipients	(n=207)	again	had	a	better	survival	than	those	239	 who	were	CMV	mismatched	(n=122)	(5yr	OS	38.6%	vs	25.8%,	p=0.002).	These	240	 findings	were	consistent	when	adjusted	for	other	significant	variables	in	a	241	 multivariate	analysis	(Figure	2b).	When	compared	to	the	HLA	matched,	CMV	242	
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matched	recipients:	there	was	a	RR	1.36	(95%	CI	1.1-1.7,	p=0.003)	for	HLA	243	 matched	and	CMV	mismatched,	a	RR	1.22	(95%	CI	0.99-1.5,	p=0.062)	for	HLA	244	 mismatched	and	CMV	matched,	and	a	RR	1.81	(95%	CI	1.4-2.3,	p<0.001)	for	HLA	245	 and	CMV	mismatched.		246	
	247	
Impact	of	donor	factors	on	other	outcomes	248	
	249	 In	multivariate	analysis,	a	mismatch	of	more	than	one	HLA	allele	(RR	2.9,	95%	CI	250	 1.2-7.3,	p=0.02)	and	the	use	of	BM	(RR	2.9,	95%	CI	1.2	–	7.3,	p=0.02)	resulted	in	251	 significantly	higher	PGF.		HLA	matching	(OR	0.63	95%CI	0.5-0.8,	p=0.002),	the	use	252	 of	BM	(OR	0.59,	95%	CI	0.4-0.8,	p=0.001)	and	CMV	seronegative	donors	(OR	0.65,	253	 95%	CI	0.5-0.9,	p=0.006)	were	associated	with	a	lower	risk	of	grade	2-4	aGVHD	254	 (Table	4).		255	 	256	
Discussion	257	
	258	 Our	results	show	that	donor	factors	remain	a	critical	determinant	of	outcome	in	259	 UD	HCT,	despite	the	changing	trends	in	transplant	practice	over	recent	eras.	We	260	 found	both	HLA	matching	and	the	recipient/donor	match	status	for	pre-261	 transplant	CMV	serostatus	to	be	the	most	significant	factors	determining	survival	262	 and	report	the	novel	finding	that	avoiding	a	CMV	mismatch	may	offset	the	263	 negative	impact	of	an	HLA	mismatch.	In	addition,	we	confirmed	the	previous	264	 observations	that	HLA	matching	and	donor	age	impact	survival.	265	 	266	
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Although	the	relationship	between	CMV	and	HLA	matching	in	this	study	is	a	novel	267	 finding,	it	is	consistent	with	observations	and	proposed	mechanisms	made	in	268	 several	recent	studies.	Historically	it	is	well	recognised	that	recipient	CMV	269	 seropositivity	(R+)	is	associated	with	an	inferior	transplant	outcome	(15,	16),	but	270	 studies	regarding	the	impact	of	donor	status	have	produced	controversial	results	271	 (3,	9,	17)	and	recommendations	for	donor	selection	based	on	this	criteria	have	272	 changed	over	time.	In	recent	years	there	is	developing	consensus	around	the	273	 selection	of	a	CMV	seromatched	donor	for	a	HCT	recipient.		274	 	275	 Individual	study	results	are	not	consistent	with	regards	to	subgroups	in	which	276	 this	selection	may	be	relevant.	Two	recent	large	EBMT	studies	report	results	277	 similar	to	ours.	In	2003,	Ljungman	et	al	(10)	reported	that	a	transplant	from	a	D+	278	 was	associated	with	improved	OS,	event-free	survival	and	decreased	TRM	279	 compared	to	a	D-	in	UD	SCT.	They	did	not	find	any	difference	in	GVHD	in	the	280	 seronegative	vs	seropositive	groups.	In	that	study	the	positive	effect	of	D+	was	281	 abrogated	by	TCD	using	ATG,	but	recipients	receiving	Alemtuzumab	(as	in	our	282	 study)	were	not	included.	More	recently	the	same	group(11)	showed	an	improved	283	 survival	in	R+	transplanted	with	a	D+,	however	only	in	the	recipients	receiving	284	 myeloablative	conditioning	regimens.	Although	CMV	reactivations	(and	GVHD)	285	 were	not	directly	addressed,	they	found	that	deaths	due	to	viral	causes	were	less	286	 likely	in	R+/D+,	leading	them	to	suggest	that	the	presence	of	CMV-specific	T	cells	287	 was	mediating	a	protective	effect	of	D+	on	survival.	Interestingly	there	was	no	288	 impact	of	TCD	noted	in	this	study.	Neither	study	addressed	the	HLA	match	status.		289	 	290	
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As	shown	in	our	results,	the	negative	effect	of	an	HLA	mismatch	may	be	abrogated	291	 somewhat	by	matching	for	CMV.	The	combined	immunological	effects	as	well	as	292	 potential	poor	graft	function	due	to	treatment	of	CMV	and	an	HLA	mismatch	293	 (GVHD,	immunosuppression	and	immune	deficiency)	are	likely	to	be	critical	and	294	 may	explain	some	of	the	discrepancies	in	earlier	studies.	This	is	supported	by	the	295	 fact	that	donor	CMV	serostatus	does	not	appear	to	have	major	significance	in	296	 HLA-identical	sibling	transplantation	outcomes	(10,	11)	as	well	as	the	finding	that	297	 CMV	reactivations	are	higher	in	the	setting	of	an	HLA	mismatch.(18)	While	the	298	 overall	rates	of	clinically	significant	GVHD	were	low,	HLA	mismatching	was	299	 associated	with	a	significant	increase	in	GVHD	as	expected.		300	 	301	 Some	(10,	18,	19),	but	not	all	(20,	21)	studies	have	shown	that	CMV	reactivation	302	 and	disease	are	more	common	in	the	setting	of	a	CMV	mismatch	(i.e.	R+/D-	303	 compared	to	R+/D+).	In	the	late	1980s	it	was	reported	that	cells	from	D+	could	304	 result	in	better	outcomes	in	the	TCD	setting	through	reduction	in	CMV	305	 disease.(22)	CMV	specific	T	cells	transferred	with	the	donor	graft	could	protect	306	 against	progressive	or	recurrent	CMV	reactivation	(19,	21)	and	therefore	be	307	 associated	with	better	outcomes.		This	effect	could	be	abrogated	or	lost	by	308	 extensive	TCD	(ex-vivo	or	ATG)	or	the	need	for	ongoing	and	intensive	309	 immunosuppression	such	as	in	GVHD.	310	 		311	 Although,	in-vivo	TCD	with	Alemtuzumab	was	used	in	over	90%	of	the	recipients	312	 in	our	study,	it	is	well	recognised	that	this	does	not	eradicate	all	T	cells	and	that	a	313	 degree	of	CMV-specific	immunity	is	retained	in	this	setting.	CMV	specific	T	cells	314	 may	also	be	of	recipient	origin.	Peggs	et	al.(23)	have	recently	shown	that	in	the	315	
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majority	of	R+/D-	recipients	receiving	TCD	(mostly	sibling)	reduced	intensity	316	 conditioning	(RIC)	HCT,	recipient-derived	T	cells	provide	protection	from	317	 recurrent	CMV	infection	in	the	absence	of	GVHD.	However,	they	stress	the	318	 importance	of	avoiding	GVHD	in	this	setting	to	prevent	CMV-associated	toxicities.	319	 In	our	registry	based	study,	we	unfortunately	do	not	have	data	on	CMV	320	 reactivations,	immune	reconstitution	(IR)	or	the	chimeric	status	of	recipients	post	321	 transplant.	However,	in	line	with	the	findings	of	Peggs	et	al’s,	the	negative	effect	of	322	 donor	serostatus	(R+/D-)	in	our	study	is	seen	predominantly	in	those	recipients	323	 with	a	co-existing	HLA	mismatch	and	consequently	an	increase	in	clinical	324	 GVHD(data	not	shown).		325	 	 	326	 Another	possible	mechanism	for	improved	outcome	may	be	through	a	direct	(24-327	 26)	or	indirect	(through	earlier	IR)	(27)	effect	of	CMV	on	reduction	of	disease	328	 relapse	post	transplant,	although	this	remains	controversial.(28-30)	Early	and	329	 robust	IR	in	general	has	been	shown	to	be	associated	with	improved	transplant	330	 outcomes.(31)	Not	surprisingly,	CMV	specific	IR	has	an	important	association	331	 with	a	reduction	in	CMV	reactivation	and	infections.(20,	32)	However	donor	CMV	332	 status	has	also	been	shown	to	influence	the	strength	of	IR	(33)	and	Zhou	et	al.	333	 showed	that	CMV	specific	T-cell	populations	from	R+/D+	contained	higher	levels	334	 of	functional	subsets	than	R+/D-recipients.(19)	We	found	that	the	use	of	CMV	335	 seronegative	donors	was	associated	with	a	lower	relapse	risk.		336	 	337	 HLA	matching	is	important	for	survival,	however	in	contrast	to	our	previous	338	 studies,	(5,	34)	we	did	not	find	a	similar	survival	between	a	10/10	and	9/10	339	 matched	transplant,	but	rather	findings	similar	to	the	Lee	et	al.	paper	(2)	showing	340	
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an	incremental	survival	disadvantage	with	additional	HLA	mismatches.	Possible	341	 reasons	for	this	include	a	reduction	in	Alemtuzumab	doses	in	the	recent	era(35,	342	 36)	as	well	as	the	larger	numbers	now	included	in	our	study	giving	us	greater	343	 power	to	detect	a	difference.		We	did	see	an	impact	of	DQB1	matching	on	both	OS	344	 and	NRM.	This	differed	from	the	Lee	et	al	(2)	study,	however	is	consistent	with	345	 the	report	from	the	German	group(9,	37)		which	found	a	higher	mortality	346	 associated	with	DQB1	mismatching,	in	particular	if	these	mismatches	were	at	an	347	 antigenic	level.	As	in	many	studies	the	type	of	mismatch	may	thus	be	of	348	 significance	and	may	differ	in	the	European	versus	American	population.	Based	349	 on	these	differences	we	would	recommend	matching	status	continue	to	be	350	 considered	for	DQB1	as	the	impact	of	mismatches	remains	somewhat	351	 controversial.	Matching	should	also	be	prioritised	for	HLA-B.	A	caution	is	that	the	352	 number	of	mismatches	in	this	study	was	small.	Although	survival	was	improved	353	 when	either	allele	level	or	epitope	matching	for	DPB1	was	performed	as	has	been	354	 previously	shown,(4,	6)	this	was	not	a	significant	factor	in	multivariate	analysis.	355	 Previously	the	impact	has	been	seen	most	commonly	in	transplant	pairs	matched	356	 for	the	other	HLA	alleles,	with	less	of	an	impact	of	DPB1	mismatching	in	≤9/10	357	 matched	transplants	and	we	did	not	perform	subset	analysis.	358	 	359	 Donor	age	was	significantly	associated	with	transplant	outcomes,	although	the	360	 effect	in	multivariate	analysis	was	borderline.	These	findings	are	consistent	with	361	 several	other	studies(9,	37)	and	suggest	this	factor	should	be	taken	into	account	362	 in	donor	selection.	Although	donor	gender	and	ABO	matching	status	both	had	363	 some	impact	on	transplant	outcomes	in	univariate	analysis,	these	effects	were	not	364	 seen	in	multivariate	analysis.	Several	other	studies	have	shown	conflicting	results	365	
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related	to	these	factors	and	it	is	possible	that	the	impact	may	differ	based	on	the	366	 characteristics	of	the	population	studied.	In	addition,	small	statistical	effects	may	367	 be	more	difficult	to	appreciate	in	smaller	datasets.		368	 	369	 In	conclusion,	our	results	add	to	the	recent	consensus	that	survival	is	improved	370	 by	selecting	a	CMV	matched	donor	for	an	UD	HCT	recipient.	We	significantly	371	 extend	these	findings	by	including	the	influence	of	HLA	matching	on	this	variable	372	 and	suggest	that	these	factors	are	closely	interrelated.	373	 	374	 Based	on	these	results,	and	those	from	recent	studies,	several	donor	selection	375	 strategies	could	be	proposed.	A	10/10	HLA	matched	donor	remains	best	and	376	 selection	of	a	CMV	matched	donor	is	preferable.	This	is	particularly	relevant	in	the	377	 setting	of	a	R+	in	the	HLA	mismatch	setting.	If	no	D+	is	available	in	this	setting	an	378	 alternative	stem	cell	source,	such	as	umbilical	cord	blood	which	has	been	shown	379	 to	be	associated	with	less	GVHD,	should	be	considered.	Where	a	R+/D-	380	 combination	cannot	be	avoided,	active	strategies	to	avoid	GVHD	should	be	381	 undertaken.	Finally	our	results	suggest	that	donor	characteristics	should	not	be	382	 considered	in	isolation,	but	as	a	‘package’	and	individualised	based	on	recipient	383	 characteristics.	384	 	385	
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Figure	legends	543	 	544	 Figure	1:	Probability	of	survival	curves	for	groups	based	on	the	degree	of	HLA	matching	545	 for	10/10	alleles:	10/10	vs	9/10	vs	<9/10	546	 	547	 Figure	2:	Survival	curves	for	groups	based	on	recipient/donor	CMV	serostatus	and	HLA	548	 matching	status.	A.	Univariate	analysis,	B.	For	an	average	patient	from	a	Cox	regression	549	 analysis	that	included	recipient	age,	disease	risk,	donor	age,	era	and	previous	autograft.		550	 	551	 	 	552	
21		
Table	1:	Recipient	and	Donor	characteristics,	presented	by	transplantation	era	553	 	554	 Variable	 1996-1999	(N=154)	 2000-2003	(N=433)	 2004-2007	(N=387)	 2008-2011	(N=297)	 P-value	(comparison	
of	eras)	 Overall	(N=1271)	HLA	Match	status					10/10					9/10				<9/10	
	98	(64%)	41	(27%)	15	(10%)	
	286	(66%)	100	(23%)	47	(11%)	
	305	(79%)	63	(16%)	19	(5%)	
	244	(82%)	50	(17%)	3	(1%)	
		<0.001	 	933	(73%)	254	(20%)	84	(7%)	HLA	Match							10/10					9/10	A	Mismatch					9/10	B	Mismatch					9/10	C	Mismatch					9/10	DQ	Mismatch					9/10	DR	Mismatch	
	98	(70.5%)	11	(7.9%)	2	(1.4%)	22	(15.8%)	6	(4.3%)	0	(0%)	
	286	(74.1%)	18	(4.7%)	11	(2.8%)	48	(12.4%)	20	(5.2%)	3	(0.8%)	
	305	(82.9%)	19	(5.2%)	5	(1.4%)	23	(6.3%)	15	(4.1%)	1	(0.3%)	
	244	(83.0%)	12	(4.1%)	4	(1.4%)	18	(6.1%)	12	(4.1%)	4	(1.4%)	
			0.007	
	933	(78.6%)	60	(5.1%)	22	(1.9%)	111	(9.4%)	53	(4.5%)	8	(0.7%)	Donor	age	(years)		median	(range)	
			missing	
	34.6	(21-53)	
1	
	35.5	(19-56)	
2	
	34.9	(20-60)	
9	
	33.2	(19-58)	
2	
	0.073	 	34.9	(19-60)	
14	Donor	age	(years)				<30				>30	 	42	(27.5%)	111	(72.5%)	 	106	(24.6%)	325	(75.4%)	 	130	(34.4%)	248	(65.6%)	 	110	(37.3%)	185	(62.7%)	 	0.001	 	388	(30.9%)	869	(69.1%)	Duration	of	disease	pre-sct	months,	median	(range)				missing	
		16.8	(1-245)	
1	
		15.0	(2-309)	
2	
		15.3	(2-381)	
9	
		13.8	(2-187)	
1	
		0.74	 		15.0	(1-381)	
13	Recipient	age	(years)	median	(range)	 	29.1	(2-57)	 	37.3	(2-66)	 	43.4	(1-72)	 	51.2	(1-71)	 	<0.001	 	40.6	(1-72)	Recipient	age	(years)				<20				20-39				40-59				>60	
	51	(33.1%)	68	(44.2%)	35	(22.7%)	0	(0%)	
	108	(24.9%)	143	(33.0%)	168	(38.8%)	14	(3.2%)	
	64	(16.5%)	102	(26.4%)	182	(47.0%)	39	(10.1%)	
	25	(8.4%)	57	(19.2%)	139	(46.8%)	76	(25.6%)	
		<0.001	 	248	(19.5%)	370	(29.1%)	524	(41.2%)	129	(10.1%)	Recipient	gender				Male				Female	 	92	(59.7%)	62	(40.3%)	 	275	(63.5%)	158	(36.5%)	 	249	(64.3%)	138	(35.7%)	 	184	(62.0%)	113	(38.0%)	 	0.76	 	800	(62.9%)	471	(37.1%)	Disease	Risk	–	EBMT	score				Good				Intermediate				Poor	
			Missing			
		73	(49.3%)	60	(40.5%)	15	(10.1%)	
6	
		184	(43.6%)	163	(38.6%)	75	(17.8%)	
11	
		183	(48.5%)	138	(3.6%)	56	(14.9%)	
10	
		140	(48.4%)	96	(33.2%)	53	(18.3%)	
8	
			0.19			
		580	(46.9%)	457	(37.0%)	199	(16.1%)	
35	Recipient	/	Donor	CMV	status				R-/D-				R-/D+				R+/D-				R+/D+				
			Missing	
		82	(55.0%)	22	(14.8%)	27	(18.0%)	18	(12.1%)	
5	
		246	(57.1%)	36	(8.4%)	88	(20.4%)	61	(14.2%)	
2	
		174	(49.3%)	23	(6.5%)	73	(20.7%)	83	(23.5%)	
34	
		145	(49.2%)	20	(6.8%)	56	(19.0%)	74	(25.1%)	
2	
			<0.001	
		647	(52.7%)	101	(8.2%)	244	(19.9%)	236	(19.2%)	
43	Recipient	/	Donor	CMV	status				matched				mismatched	
			Missing	
		100	(67.1%)	49	(22.9%)	
5	
		307	(71.2%)	124	(28.8%)	
2	
		257	(72.8%)	96	(27.2%)	
34	
		219	(74.2%)	76	(25.8%)	
2	
		0.44	 		883	(71.9%)	345	(28.1%)	
43	Stem	cell	source				BM				PBSC				Missing	
	146	(96.7%)	5	(3.3%)	
3	
	268	(62.3%)	162	(37.7%)	
3	
	122	(31.7%)	263	(68.3%)	
2	
	44	(14.9%)	252	(85.1%)	
1	
	<0.001	 	580	(46.0%)	682	(54.0%)	
9	Conditioning	regimen				Myeloablative				Reduced	Intensity	
			Missing		
	 133	(93.7%)	9	(6.3%)	
12	
	268	(63.8%)	152	(36.2%)	
13	
	 169	(43.7%)	218	(56.3%)	
0	
	 91	(30.6%)	206	(69.4%)	
0	
		<0.001	 	 661	(53.0%)	585	(47.0%)	
25	Previous	autograft				0				>0	 	138	(89.6%)	16	(10.4%)	 	367	(84.8%)	66	(15.2%)	 	315	(81.4%)	72	(18.6%)	 	259	(87.2%)	38	(12.8%)	 	0.055	 	1079	(84.9%)	192	(15.1%)	T-cell	depletion	(Campath)				Yes				No	
			Missing	
		129	(94.2%)	8	(5.8%)	
17	
		357	(94.9%)	19	(5.1)	
57	
		308	(90.6%)	32	(9.4%)	
47	
		246	(94.3%)	15	(5.7%)	
36	
		0.10	 		1040	(93.4%)	74	(6.6%)	
157	BM-bone	marrow;	PBSC-peripheral	blood	stem	cells	 	555	
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Table	2:		Univariate	analyses	of	Recipient	and	Donor	Factors	on	OS	and	NRM	and	relapse	556	 	557	 	558	 	 N	 Survival	at	
5yrs	(%)	
(95%CI)	 p-value	 N	 NRM	at	1yr(%)	(95%	CI)	 p-value	 N	 Relapse	at	5yrs	(%)	(95%CI)	 p-value	Overall	 1271	 40.6	(38-44)	 -	 1236	 26.5	(24-29)	 -	 1236	 42.1	(39-45)	 	HLA	match	status				10/10				1	Mismatch			>1	Mismatch	
	933	254	84	
	43.1	(40-47)	35.6	(30-42)	28.4	(20-40)	
		0.001	 	905	247	84	
	20.3	(27-23)	26.1	(21-32)	33.4	(24-45)	
		0.007	 	905	247	84	
	42.1	(39-46)	41.5	(36-48)	44.1	(34-57)	
		0.96	HLA	Match				12/12				10/10					9/10	A	Mismatch					9/10	B	Mismatch					9/10	C	Mismatch					9/10	DR	Mismatch					9/10	DQ	Mismatch	
	140	793	60	22	111	8	53	
	46.5	(38-57)	42.5	(39-46)	36.1	(26-51)	22.7	(11-49)	39.0	(31-49)	46.9	(21-99)	31.7	(21-48)	
			0.011	
	134	771	57	21	110	8	51	
	18.3	(13-26)	20.6	(18-24)	24.8	(16-39)	38.1	(22-67)	21.8	(15-31)	12.5	(2-89)	34.9	(24-52)	
			0.16		
	134	771	57	21	110	8	51	
	44.7	(36-55)	41.6	(38-46)		41.8	(30-58)	38.1	(21-68)	44.7	(36-55)	25.0	(7-92)	37.8	(26-55)	
			0.97	
TCE-Matching	status				Match				TCEM				TCED	
	175	639	447	
	41.5(34-50)	43.0	(39-47)	36.9	(32-42)	
		0.054	 	169	623	434	
	23.6	(18-31)	19.3	(16-23)	26.4	(23-31)	
		0.028	 	169	623	434	
	43.1	(36-52)	45.3	(41-50)	36.8	(32-42)	
		0.036	HLA	A				10/10				9/10	A	match				9/10	A	Mismatch	
	933	194	60	
	43.1	(40-47)	35.5	(29-43)	36.1	(25-51)	
			0.17*	
	905	190	57	
	20.3	(18-23)	26.6	(21-34)	24.8	(16-39)	
		0.14	 	905	190	57	
	42.1	(39-46)	41.5	(35-49)	41.8	(30-58)	
		0.99	HLA	B				10/10				9/10	B	match				9/10	B	Mismatch	
	933	232	22	
	43.1	(40-47)	36.8	(31-44)	22.7	(11-49)	
			0.011*	
	905	226	21	
	20.3	(18-23)	25.0	(20-31)	38.1	(22-67)	
		0.059	 	905	226	21	
	42.1	(39-46)	41.9	(36-49)	38.1	(21-68)	
		0.95	HLA	C				10/10				9/10	C	match				9/10	C	Mismatch	
	933	143	111	
	43.1	(40-47)	33.1	(26-42)	39.0	(31-49)	
			0.28*	
	905	137	110	
	20.3	(18-23)	29.7	(23-39)	25.8	(19-34)	
		0.062	 	905	137	110	
	42.1	(39-46)	38.8	(31-48)	44.7	(36-55)	
		0.74	HLA	DR				10/10				9/10	DR	match				9/10	DR	Mismatch	
	933	246	8	
	43.1	(40-47)	35.3	(30-42)	46.9	(18-78)	
			0.75*	
	905	239	8	
	20.3	(18-23)	26.6	(22-33)	12.5	(2-89)	
		0.11	 	905	239	8	
	42.1	(39-46)	42.1	(36-49)	25.0	(7-92)	
		0.69	HLA	DQ				10/10				9/10	DQ	match				9/10	DQ	Mismatch	
	933	201	53	
	43.1	(40-47)	36.7	(30-44)	31.7	(21-48)	
			0.03*	
	905	196	51	
	20.3	(18-23)	24.0	(19-31)	34.9	(24-52)	
		0.051	 	905	196	51	
	42.1	(39-46)	42.4	(36-50)	37.8	(26-55)	
		0.95	Donor	age	(years)				<30				>30	 	388	869	 	45.3	(40-51)	38.6	(35-42)	 	0.01	 	376	846	 	19.2	(16-27)	27.9	(24-32)	 	0.075	 	376	846	 	39.5	(35-45)	43.6	(40-47)	 	0.18	Recipient	age	(years)				<20				20-39				40-59				>60	
	248	370	524	129	
	45.7	(39-52)	44.9	(40-50)	38.5	(34-43)	23.5	(16-33)	
		0.005	 	248	370	524	129	
	21.1	(17-27)	20.9	(17-26)	22.5	(19-27)	29.2	(22-39)	
		0.41	 	248	370	524	129	
	40.2	(34-47)	44.0	(39-50)	43.6	(39-48)	34.5	(26-45)	
		0.07	
Recipient	CMV				Negative				Positive	 	749	480	 	44.3	(41-48)	35.1	(31-40)	 	0.013	 	731	463	 	20.4	(18-24)	25.2	(22-30)	 	0.057	 	731	463	 	42.6	(39-47)	42.2	(38-47)	 	0.66	Donor	CMV				Negative				Positive	 	926	344	 	40.9	(38-44)	39.7	(35-46)	 	0.78	 	899	336	 	23.3	(21-26)	19.9	(16-25)	 	0.19	 	899	336	 	40.4	(37-44)	46.7	(41-53)	 	0.076	Recipient	/	Donor	CMV				R-/D-				R-/D+				R+/D-				R+/D+	
	647	101	244	236	
	45.3	(41-49)	37.9	(29-48)	30.0	(24-36)	40.5	(34-48)	
		<0.001	 	631	99	233	230	
	19.6	(17-23)	25.4	(18-36)		32.6	(27-39)		17.7	(13-24)	
		<0.001	 	631	99	233	230	
	41.5	(38-46)	49.1	(40-61)	38.9	(33-46)	45.3	(39-53)	
		0.30	
Recipient	/	Donor	CMV				Matched				Mismatched	 	883	345	 	44.1	(41-48)	32.2	(28-38)	 	<0.001	 	861	332	 	19.1	(17-22)	30.4	(26-36)	 	<0.001	 	861	332	 	42.5	(39-46)	41.9	(37-48)	 	0.61	Donor	Sex				Male				Female	 	1022	249	 	41.1	(38-45)	38.3	(32-45)	 	0.26	 	989	247	 	20.9	(19-24)	28.2	(23-35)	 	0.011	 	989	247	 	42.0	(39-45)	42.3	(36-49)		 	0.91	Recipient	/	Donor	Sex				Other	combination				Male	/	Female	 	1138	133	 	41.3	(38-44)	34.8	(27-44)	 	0.11	 	1103	133	 	21.4	(19-24)	30.4	(23-39)	 	0.018		 	1103	133	 	42.1	(39-45)	42.2	(24-52)	 	0.94	
23		
Stem	cell	source				BM				PBSC	 	580	682	 	38.9	(35-43)	42.2	(38-47)	 	0.078	 	561	666	 	25.0	(22-29)	20.4	(18-24)	 	0.027	 	561	666	 	45.2	(41-50)	38.7	(35-43)	 	0.024	R/D	ABO	matching					Match					Minor	mismatch					Major	mismatch					Bidirectional	
	557	310	283	78	
	40.9	(37-46)	46.5	(41-53)	33.9	(29-40)	36.8	(27-50)	
		0.011	 	537	303	277	76	
	20.0	(17-23)	20.5	(16-26)	29.1	(24-35)	22.8	(15-35)	
		0.040	 	537	303	277	76	
	42.0	(38-47)	39.8	(34-46)	42.1	(36-49)	46.4	(36-60)	
		0.69	
Duration	of	disease	pre	SCT				<1y				>1y	 	532	736	 	41.7	(37-46)	39.9	(36-44)	 	0.92	 	579	704	 	21.6	(18-26)	22.7	(20-26)	 	0.60	 	579	704	 	41.3	(37-46)	43.1	(39-47)	 	0.83	Previous	autograft				0				>0	 	1079	192	 	42.9	(38-44)	27.1	(21-35)	 	0.001	 	1050	186	 	22.3	(20-25)	22.9	(18-30)	 	0.78	 	1050	186	 	40.0	(37-43)	54.2	(47-62)	 	<0.001		ERA				96-99				00-03				04-07				08-11	
	154	433	387	297	
	40.8	(34-49)	39.5	(35-44)	42.5	(38-48)	37.8	(31-46)	
		0.64	 	148	420	377	291	
	33.8	(27-42)	20.7	(17-25)	20.5	(17-25)	21.8	(17-27)	
		0.003	 	148	420	377	291	
	44.2	(37-53)	47.2	(43-52)	39.0	(34-44)	35.7	(30-43)	
		0.012	
Disease	Risk	-	EBMT	score					Good				Intermediate				Poor	
	580	457	199	
	47.5	(43-52)	34.7	(30-40)	31.7	(25-40)	
		<0.001	 	563	444	194	
	20.2	(20-27)	24.5	(21-29)	23.6	(18-31)	
		0.26	 	563	444	194	
	41.6	(38-46)	42.6	(38-48)	46.0	(39-54)	
		0.17	Conditioning	regimen				Myeloablative				Reduced	intensity	 	661	585	 	41.4	(38-45)	40.0	(36-45)		 	0.33	 	647	565	 	24.8	(22-28)	19.8	(17-23)	 	0.016	 	647	565	 	41.2	(38-45)	42.4	(38-47)	 	0.71	BM-bone	marrow;	PBSC-peripheral	blood	stem	cells;	TCE-T	cell	epitope;	TCEM	-T	cell	epitope	match;	TCED	-T	cell	epitope	559	 disparate;		560	 	561	 *p-values	are	between	mismatched	genotype	and	10/10	match	562	 	 	563	
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Table	3:		Multivariate	analysis	of	Survival	and	NRM	564	 	565	 	 Overall	Survival	 Non	Related	Mortality		 N	 RR	(95%	CI)	 p-value	 N	 RR	(95%	CI)	 p-value	HLA	Match				10/10	Match					1	Mismatch				>1	Mismatch	 	878	239	77	 	1.00	1.21	(1.1-1.5)	1.43	(1.1-1.9)	 		0.042	0.016	 	871	239	83	 	1.00	1.24	(0.9-1.6)	1.59	(1.1-2.4)	 		0.14	0.028	Recipient	Donor	CMV				Match				Mismatch	 	 863	331	 	 1.00	1.40	(1.2-1.6)	 		 <0.001	 	 861	332	 	 1.00	1.63	(1.3-2.1)	 	 	<0.001	Recipient	age	(years)				<20				20-39				40-59				>60	
	221	351	497	125	
	1.00	1.07	(0.8-1.4)	1.26	(1.0-1.6)	1.71	(1.3-2.3)	
		0.57	0.047	0.001	
	 	 	
Previous	autos				0				>0	 	1014	180	 	1.00	1.42	(1.2-1.8)	 		0.001	 	 	 	Donor	Age				<30y				>30y	 	372	822	 	1.00	1.17	(0.98-1.4)	 		0.078	 	 	 	ERA				96-99				00-03				04-07				08-11	
	142	421	345	286	
	1.00	0.84	(0.7-1.1)	0.76	(0.6-1.0)	0.77	(0.6-1.1)	
		0.18	0.049	0.078	
	143	418	343	289	
	1.00	0.57	(0.4-0.8)	0.54	(0.4-0.9)	0.60	(0.3-0.7)	
		0.002	0.002	0.001	Disease	Risk	-	EBMT				Good				Intermediate				Poor	
	 557	444	193	
	 1.00	1.37	(1.2-1.6)	1.33	(1.1-1.7)	
	 	<0.001	0.013	
	 	 	
Recipient	/	Donor	Sex				Other	combination				Male	/	Female	 	 	 	 	1061	132	 	1.00	1.38	(0.99-1.9)	 		0.063		566	
	567	
	 	568	
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Table	4:		Multivariate	analysis	of	PGF,	aGVHD	and	Relapse	569	 	570	 	 Primary	Graft	Failure	 	Acute	GVHD	grade	2-4	 Relapse		 N	 OR	(95%	CI)	 p-value	 N	 OR	(95%	CI)	 p-value	 N	 RR	(95%	CI)	 p-value	HLA	Match				10/10	Match					1	Mismatch				>1	Mismatch	 	872	233	76	 	1.00	1.7	(0.8-3.5)	2.9		(1.2	–	7.3)	 		0.15	0.02	 	882	237	77	 	1.00	1.52	(1.1	-2.2)	1.82	(1.1	–	3.0)	 		0.01	0.022	 	 	 	Donor	CMV				Negative				Positive	 	 	 	 	 		 	 	 875	321	 	 1.00	0.65	(0.5-0.9)	 	 	0.005	 	 899				336	 	 1.00	1.23	(1.1-1.5)	 		0.035	Stem	cell	source				PBSC					BM				 	655	526	 	1.00	4.23	(1.8-9.7)	 		0.001	 	542	654	 	1.00	0.58	(0.4	-0.8)	 		0.001	 	 	 	ERA				96-99				00-03				04-07				08-11	
	 		 		 134	413	372	277	
	1.00	0.31	(0.2-0.5)	0.39	(0.2-0.6)	0.28	(0.2-0.5)	
		<0.001	<0.001	<0.001	
	147	420	377	291	
	1.00	1.09	(0.8-1.5)	0.83	(0.6-1.1)	0.70	(0.5-0.9)	
		0.54	0.21	0.031	Conditioning	type				Reduced			Intensity			Myeloablative	
	 	554		627	
	 	1.00		8.2	(2.5-27.2)	
	 			0.001	
	 	 	 	 	 	
Previous	autos				0				>0	 	 	 	 	 	 	 	1049	186	 	1.00	1.55	(1.2-1.9)	 		<0.001		 	571	
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